{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:51:22Z","timestamp":1792929082965,"version":"4.5.0"},"reference-count":271,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40266-023-01019-3","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T06:02:35Z","timestamp":1679983355000},"page":"499-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Safety and Tolerability of Antimicrobial Agents in the Older Patient"],"prefix":"10.1007","volume":"40","author":[{"given":"Luca","family":"Soraci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cherubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualina","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elsa","family":"Gambuzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Filicetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7276-3256","authenticated-orcid":false,"given":"Andrea","family":"Corsonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Lattanzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"1019_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.idc.2007.07.006","volume":"21","author":"TH Htwe","year":"2007","unstructured":"Htwe TH, Mushtaq A, Robinson SB, Rosher RB, Khardori N. Infection in the elderly. Infect Dis Clin N Am. 2007;21:711\u201343. https:\/\/doi.org\/10.1016\/j.idc.2007.07.006. (ix).","journal-title":"Infect Dis Clin N Am"},{"key":"1019_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s1473-3099(02)00437-1","volume":"2","author":"G Gavazzi","year":"2002","unstructured":"Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2:659\u201366. https:\/\/doi.org\/10.1016\/s1473-3099(02)00437-1.","journal-title":"Lancet Infect Dis"},{"key":"1019_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1183\/09031936.03.00064102","volume":"21","author":"R Zalacain","year":"2003","unstructured":"Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, Esteban L, Menendez R, Blanquer R, Borderias L. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J. 2003;21:294\u2013302. https:\/\/doi.org\/10.1183\/09031936.03.00064102.","journal-title":"Eur Respir J"},{"issue":"Suppl 1A","key":"1019_CR4","doi-asserted-by":"publisher","first-page":"5S","DOI":"10.1016\/s0002-9343(02)01054-9","volume":"113","author":"B Foxman","year":"2002","unstructured":"Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S-13S. https:\/\/doi.org\/10.1016\/s0002-9343(02)01054-9.","journal-title":"Am J Med"},{"key":"1019_CR5","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1007\/s10620-008-0278-y","volume":"53","author":"H Gregersen","year":"2008","unstructured":"Gregersen H, Pedersen J, Drewes AM. Deterioration of muscle function in the human esophagus with age. Dig Dis Sci. 2008;53:3065\u201370. https:\/\/doi.org\/10.1007\/s10620-008-0278-y.","journal-title":"Dig Dis Sci"},{"key":"1019_CR6","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.cgh.2007.08.011","volume":"5","author":"J Lee","year":"2007","unstructured":"Lee J, Anggiansah A, Anggiansah R, Young A, Wong T, Fox M. Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol. 2007;5:1392\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2007.08.011.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 5A","key":"1019_CR7","doi-asserted-by":"publisher","first-page":"8S","DOI":"10.1016\/j.amjmed.2004.07.019","volume":"117","author":"DA Greenwald","year":"2004","unstructured":"Greenwald DA. Aging, the gastrointestinal tract, and risk of acid-related disease. Am J Med. 2004;117(Suppl 5A):8S-13S. https:\/\/doi.org\/10.1016\/j.amjmed.2004.07.019.","journal-title":"Am J Med"},{"key":"1019_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jama.1997.03550080091047","volume":"278","author":"M Feldman","year":"1997","unstructured":"Feldman M. The mature stomach. Still pumping out acid? JAMA. 1997;278:681\u20132.","journal-title":"JAMA"},{"key":"1019_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1046\/j.1523-5378.2000.00003.x","volume":"5","author":"K Haruma","year":"2000","unstructured":"Haruma K, Hamada H, Mihara M, Kamada T, Yoshihara M, Sumii K, Kajiyama G, Kawanishi M. Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: case-control study in Japan. Helicobacter. 2000;5:24\u20139. https:\/\/doi.org\/10.1046\/j.1523-5378.2000.00003.x.","journal-title":"Helicobacter"},{"key":"1019_CR10","first-page":"624","volume":"53","author":"K Nakamura","year":"2006","unstructured":"Nakamura K, Ogoshi K, Makuuchi H. Influence of aging, gastric mucosal atrophy and dietary habits on gastric secretion. Hepatogastroenterology. 2006;53:624\u20138.","journal-title":"Hepatogastroenterology"},{"key":"1019_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000048863","volume":"64","author":"R Lamberts","year":"2001","unstructured":"Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001;64:205\u201313. https:\/\/doi.org\/10.1159\/000048863.","journal-title":"Digestion"},{"key":"1019_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.017","author":"OS Boxel","year":"2009","unstructured":"Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Socio-demographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2009. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.017.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"1019_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-011-0680-x","volume":"6","author":"T Mazzei","year":"2011","unstructured":"Mazzei T. The difficulties of polytherapy: examples from antimicrobial chemotherapy. Intern Emerg Med. 2011;6(Suppl 1):103\u20139. https:\/\/doi.org\/10.1007\/s11739-011-0680-x.","journal-title":"Intern Emerg Med"},{"key":"1019_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1086\/596503","volume":"48","author":"M Iwamoto","year":"2009","unstructured":"Iwamoto M, Wenning LA, Nguyen BY, Teppler H, Moreau AR, Rhodes RR, Hanley WD, Jin B, Harvey CM, Breidinger SA, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48:489\u201392. https:\/\/doi.org\/10.1086\/596503.","journal-title":"Clin Infect Dis"},{"key":"1019_CR15","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00224.2002","author":"JW Wiley","year":"2002","unstructured":"Wiley JW. Aging and neural control of the GI tract: III. Senescent enteric nervous system: lessons from extraintestinal sites and nonmammalian species. Am J Physiol Gastrointest Liver Physiol. 2002. https:\/\/doi.org\/10.1152\/ajpgi.00224.2002.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1019_CR16","doi-asserted-by":"publisher","first-page":"G1226","DOI":"10.1152\/ajpgi.00276.2002","volume":"283","author":"WC Orr","year":"2002","unstructured":"Orr WC, Chen CL. Aging and neural control of the GI tract: IV. Clinical and physiological aspects of gastrointestinal motility and aging. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1226\u201331. https:\/\/doi.org\/10.1152\/ajpgi.00276.2002.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1019_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000058351","volume":"48","author":"R Ciccocioppo","year":"2002","unstructured":"Ciccocioppo R, Di Sabatino A, Luinetti O, Rossi M, Cifone MG, Corazza GR. Small bowel enterocyte apoptosis and proliferation are increased in the elderly. Gerontology. 2002;48:204\u20138. https:\/\/doi.org\/10.1159\/000058351.","journal-title":"Gerontology"},{"key":"1019_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ejpb.2008.05.011","volume":"70","author":"W Weitschies","year":"2008","unstructured":"Weitschies W, Friedrich C, Wedemeyer RS, Schmidtmann M, Kosch O, Kinzig M, Trahms L, Sorgel F, Siegmund W, Horkovics-Kovats S, et al. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur J Pharm Biopharm. 2008;70:641\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2008.05.011.","journal-title":"Eur J Pharm Biopharm"},{"key":"1019_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1532-5415.1995.tb06382.x","volume":"43","author":"JR Saltzman","year":"1995","unstructured":"Saltzman JR, Kowdley KV, Perrone G, Russell RM. Changes in small-intestine permeability with aging. J Am Geriatr Soc. 1995;43:160\u20134. https:\/\/doi.org\/10.1111\/j.1532-5415.1995.tb06382.x.","journal-title":"J Am Geriatr Soc"},{"key":"1019_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2165\/00003088-198917040-00003","volume":"33","author":"MT Kinirons","year":"1997","unstructured":"Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet. 1997;33:302\u201312. https:\/\/doi.org\/10.2165\/00003088-198917040-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1019_CR21","doi-asserted-by":"publisher","first-page":"e4800","DOI":"10.7759\/cureus.4800","volume":"11","author":"XC Ruan","year":"2019","unstructured":"Ruan XC, Tan PY, Tan Y. Clarithromycin and glipizide drug-drug interaction leading to refractory hypoglycemia. Cureus. 2019;11:e4800\u2013e4800. https:\/\/doi.org\/10.7759\/cureus.4800.","journal-title":"Cureus."},{"key":"1019_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2014.3293","volume":"174","author":"TM Parekh","year":"2014","unstructured":"Parekh TM, Raji M, Lin Y-L, Tan A, Kuo Y-F, Goodwin JS. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med. 2014;174:1605\u201312. https:\/\/doi.org\/10.1001\/jamainternmed.2014.3293.","journal-title":"JAMA Intern Med"},{"key":"1019_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266471","volume":"17","author":"SH Liao","year":"2022","unstructured":"Liao SH, Hu SY, How CK, Hsieh VC, Chan CM, Chiu CS, Hsieh MS. Risk for hypoglycemic emergency with levofloxacin use, a population-based propensity score matched nested case-control study. PLoS ONE. 2022;17: e0266471. https:\/\/doi.org\/10.1371\/journal.pone.0266471.","journal-title":"PLoS ONE"},{"key":"1019_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1046\/j.1365-2125.2000.00261.x","volume":"50","author":"JF Westphal","year":"2000","unstructured":"Westphal JF. Macrolide\u2014induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50:285\u201395. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00261.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1019_CR25","first-page":"25","volume":"8","author":"JM Pereira","year":"2013","unstructured":"Pereira JM, Paiva JA. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol. 2013;8:25\u201338.","journal-title":"Curr Clin Pharmacol"},{"key":"1019_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/0026-0495(70)90062-4","volume":"19","author":"GB Forbes","year":"1970","unstructured":"Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 1970;19:653\u201363. https:\/\/doi.org\/10.1016\/0026-0495(70)90062-4.","journal-title":"Metabolism"},{"key":"1019_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1172\/JCI107938","volume":"55","author":"U Klotz","year":"1975","unstructured":"Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975;55:347\u201359. https:\/\/doi.org\/10.1172\/JCI107938.","journal-title":"J Clin Invest"},{"key":"1019_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00002512-200017050-00003","volume":"17","author":"CG Hanratty","year":"2000","unstructured":"Hanratty CG, McGlinchey P, Johnston GD, Passmore AP. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging. 2000;17:353\u201362. https:\/\/doi.org\/10.2165\/00002512-200017050-00003.","journal-title":"Drugs Aging"},{"key":"1019_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/00002512-199710040-00003","volume":"10","author":"K Morike","year":"1997","unstructured":"Morike K, Schwab M, Klotz U. Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging. 1997;10:259\u201377. https:\/\/doi.org\/10.2165\/00002512-199710040-00003.","journal-title":"Drugs Aging"},{"key":"1019_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/00003495-198325050-00003","volume":"37","author":"PE Rolan","year":"1994","unstructured":"Rolan PE. Plasma protein binding displacement interactions\u2014why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37:125\u20138. https:\/\/doi.org\/10.2165\/00003495-198325050-00003.","journal-title":"Br J Clin Pharmacol"},{"key":"1019_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1067\/mcp.2002.121829","volume":"71","author":"LZ Benet","year":"2002","unstructured":"Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115\u201321. https:\/\/doi.org\/10.1067\/mcp.2002.121829.","journal-title":"Clin Pharmacol Ther"},{"key":"1019_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1211\/002235702540","volume":"55","author":"H Koyama","year":"2003","unstructured":"Koyama H, Mori S, Sugioka N, Nishihara T, Nakajima K. Age-related alteration of haloperidol-serum protein binding. J Pharm Pharmacol. 2003;55:77\u201383. https:\/\/doi.org\/10.1211\/002235702540.","journal-title":"J Pharm Pharmacol"},{"issue":"297\u2013321","key":"1019_CR33","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.2165\/00003088-200847050-00002","volume":"47","author":"JM Butler","year":"2008","unstructured":"Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47(297\u2013321):4752. https:\/\/doi.org\/10.2165\/00003088-200847050-00002.","journal-title":"Clin Pharmacokinet"},{"key":"1019_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2008.02.002","author":"AL Bartels","year":"2008","unstructured":"Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ, van Oostrom JC, Leenders KL. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. 2008. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2008.02.002.","journal-title":"Neurobiol Aging"},{"key":"1019_CR35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.clpt.2006.02.004","volume":"79","author":"R Toornvliet","year":"2006","unstructured":"Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79:540\u20138. https:\/\/doi.org\/10.1016\/j.clpt.2006.02.004.","journal-title":"Clin Pharmacol Ther"},{"key":"1019_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12149-009-0336-3","volume":"24","author":"R Arakawa","year":"2010","unstructured":"Arakawa R, Ito H, Okumura M, Morimoto T, Seki C, Takahashi H, Takano A, Suhara T. No inhibitory effect on P-glycoprotein function at blood-brain barrier by clinical dose of clarithromycin: a human PET study with [(1)(1)C]verapamil. Ann Nucl Med. 2010;24:83\u20137. https:\/\/doi.org\/10.1007\/s12149-009-0336-3.","journal-title":"Ann Nucl Med"},{"key":"1019_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1258\/136218005775544589","volume":"11","author":"H Wynne","year":"2005","unstructured":"Wynne H. Drug metabolism and ageing. J Br Menopause Soc. 2005;11:51\u20136.","journal-title":"J Br Menopause Soc"},{"key":"1019_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00003088-200544020-00004","volume":"44","author":"DG Le Couteur","year":"2005","unstructured":"Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet. 2005;44:187\u2013200. https:\/\/doi.org\/10.2165\/00003088-200544020-00004. (4424).","journal-title":"Clin Pharmacokinet"},{"key":"1019_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/00003088-199834050-00003","volume":"34","author":"DG Le Couteur","year":"1998","unstructured":"Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet. 1998;34:359\u201373. https:\/\/doi.org\/10.2165\/00003088-199834050-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1019_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000052829","volume":"48","author":"J Zeeh","year":"2002","unstructured":"Zeeh J, Platt D. The aging liver: structural and functional changes and their consequences for drug treatment in old age. Gerontology. 2002;48:121\u20137. https:\/\/doi.org\/10.1159\/000052829.","journal-title":"Gerontology"},{"key":"1019_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000065506","volume":"48","author":"A Anantharaju","year":"2002","unstructured":"Anantharaju A, Feller A, Chedid A. Aging liver. A review. Gerontology. 2002;48:343\u201353. https:\/\/doi.org\/10.1159\/000065506.","journal-title":"Gerontology"},{"key":"1019_CR42","first-page":"95","volume":"15","author":"T Tateishi","year":"1995","unstructured":"Tateishi T, Fujimura A, Shiga T, Ohashi K, Ebihara A. Influence of aging on the oxidative and conjugative metabolism of propranolol. Int J Clin Pharmacol Res. 1995;15:95\u2013101.","journal-title":"Int J Clin Pharmacol Res"},{"issue":"Suppl 2","key":"1019_CR43","doi-asserted-by":"publisher","first-page":"215S","DOI":"10.2165\/00003495-198500301-00004","volume":"18","author":"RO Davies","year":"1984","unstructured":"Davies RO, Gomez HJ, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol. 1984;18(Suppl 2):215S-229S. https:\/\/doi.org\/10.2165\/00003495-198500301-00004.","journal-title":"Br J Clin Pharmacol"},{"key":"1019_CR44","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2165\/00002512-200118110-00005","volume":"18","author":"DL Schmucker","year":"2001","unstructured":"Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18:837\u201351. https:\/\/doi.org\/10.2165\/00002512-200118110-00005.","journal-title":"Drugs Aging"},{"key":"1019_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00228-007-0422-1","volume":"64","author":"S Shi","year":"2008","unstructured":"Shi S, Morike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol. 2008;64:183\u201399. https:\/\/doi.org\/10.1007\/s00228-007-0422-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1019_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2174\/092986707780090981","volume":"14","author":"V Wauthier","year":"2007","unstructured":"Wauthier V, Verbeeck RK, Calderon PB. The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem. 2007;14:745\u201357. https:\/\/doi.org\/10.2174\/092986707780090981.","journal-title":"Curr Med Chem"},{"key":"1019_CR47","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2125.2004.02096.x","volume":"57","author":"MT Kinirons","year":"2004","unstructured":"Kinirons MT, O\u2019Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol. 2004;57:540\u20134. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02096.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1019_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/oxfordjournals.bmb.a072387","volume":"46","author":"KW Woodhouse","year":"1990","unstructured":"Woodhouse KW, James OF. Hepatic drug metabolism and ageing. Br Med Bull. 1990;46:22\u201335. https:\/\/doi.org\/10.1093\/oxfordjournals.bmb.a072387.","journal-title":"Br Med Bull"},{"key":"1019_CR49","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1177\/0091270006292249","volume":"46","author":"MB O'Connell","year":"2006","unstructured":"O\u2019Connell MB, Frye RF, Matzke GR, St Peter JV, Willhite LA, Welch MR, Kowal P, LaValleur J. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol. 2006;46:1299\u2013307. https:\/\/doi.org\/10.1177\/0091270006292249.","journal-title":"J Clin Pharmacol"},{"key":"1019_CR50","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/s0278-6915(02)00117-5","volume":"40","author":"JL Dorne","year":"2002","unstructured":"Dorne JL, Walton K, Slob W, Renwick AG. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem Toxicol. 2002;40:1633\u201356. https:\/\/doi.org\/10.1016\/s0278-6915(02)00117-5.","journal-title":"Food Chem Toxicol"},{"key":"1019_CR51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.taap.2004.01.010","volume":"199","author":"A Parkinson","year":"2004","unstructured":"Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199:193\u2013209. https:\/\/doi.org\/10.1016\/j.taap.2004.01.010.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1019_CR52","doi-asserted-by":"publisher","first-page":"B315","DOI":"10.1093\/gerona\/53a.5.b315","volume":"53","author":"DL Schmucker","year":"1998","unstructured":"Schmucker DL. Aging and the liver: an update. J Gerontol A Biol Sci Med Sci. 1998;53:B315\u201320. https:\/\/doi.org\/10.1093\/gerona\/53a.5.b315.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1019_CR53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414\u201323.","journal-title":"J Pharmacol Exp Ther"},{"key":"1019_CR54","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1067\/mcp.2000.106872","volume":"67","author":"K Dilger","year":"2000","unstructured":"Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther. 2000;67:512\u201320. https:\/\/doi.org\/10.1067\/mcp.2000.106872.","journal-title":"Clin Pharmacol Ther"},{"key":"1019_CR55","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0009-9236(98)90106-0","volume":"63","author":"HP Platten","year":"1998","unstructured":"Platten HP, Schweizer E, Dilger K, Mikus G, Klotz U. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther. 1998;63:552\u201360. https:\/\/doi.org\/10.1016\/S0009-9236(98)90106-0.","journal-title":"Clin Pharmacol Ther"},{"key":"1019_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/17425250903329095","volume":"6","author":"N Shakunthala","year":"2010","unstructured":"Shakunthala N. New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome. Expert Opin Drug Metab Toxicol. 2010;6:1\u201315. https:\/\/doi.org\/10.1517\/17425250903329095.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1019_CR57","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1345\/aph.19138","volume":"34","author":"MP Pai","year":"2000","unstructured":"Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother. 2000;34:495\u2013513. https:\/\/doi.org\/10.1345\/aph.19138.","journal-title":"Ann Pharmacother"},{"key":"1019_CR58","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2165\/00003088-200544090-00003","volume":"44","author":"J Shi","year":"2005","unstructured":"Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44:915\u201334. https:\/\/doi.org\/10.2165\/00003088-200544090-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1019_CR59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1365-2125.2007.02970.x","volume":"65","author":"SK Quinney","year":"2008","unstructured":"Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol. 2008;65:98\u2013109. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02970.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1019_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cmi.2014.09.011","volume":"21","author":"A Corsonello","year":"2015","unstructured":"Corsonello A, Abbatecola AM, Fusco S, Luciani F, Marino A, Catalano S, Maggio MG, Lattanzio F. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Clin Microbiol Infect. 2015;21:20\u20136. https:\/\/doi.org\/10.1016\/j.cmi.2014.09.011.","journal-title":"Clin Microbiol Infect"},{"key":"1019_CR61","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/phar.2450","volume":"40","author":"S Lee","year":"2020","unstructured":"Lee S, Ock M, Kim HS, Kim H. Effects of co-administration of sulfonylureas and antimicrobial drugs on hypoglycemia in patients with type 2 diabetes using a case-crossover design. Pharmacotherapy. 2020;40:902\u201312. https:\/\/doi.org\/10.1002\/phar.2450.","journal-title":"Pharmacotherapy"},{"key":"1019_CR62","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2147\/tcrm.S214938","volume":"15","author":"A Abu Mellal","year":"2019","unstructured":"Abu Mellal A, Hussain N, Said AS. The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies. Ther Clin Risk Manag. 2019;15:921\u201336. https:\/\/doi.org\/10.2147\/tcrm.S214938.","journal-title":"Ther Clin Risk Manag"},{"key":"1019_CR63","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1503\/cmaj.100702","volume":"183","author":"AJ Wright","year":"2011","unstructured":"Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ Can Med Assoc J = journal de l\u2019Association medicale canadienne. 2011;183:303\u20137. https:\/\/doi.org\/10.1503\/cmaj.100702.","journal-title":"CMAJ Can Med Assoc J = journal de l'Association medicale canadienne"},{"key":"1019_CR64","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.mcna.2006.06.008","volume":"90","author":"MP Pai","year":"2006","unstructured":"Pai MP, Momary KM, Rodvold KA. Antibiotic drug interactions. Med Clin N Am. 2006;90:1223\u201355. https:\/\/doi.org\/10.1016\/j.mcna.2006.06.008.","journal-title":"Med Clin N Am"},{"key":"1019_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000157","volume":"6","author":"LY Park-Wyllie","year":"2009","unstructured":"Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med. 2009;6: e1000157. https:\/\/doi.org\/10.1371\/journal.pmed.1000157.","journal-title":"PLoS Med"},{"key":"1019_CR66","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","volume":"169","author":"SS Gill","year":"2009","unstructured":"Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, Rochon PA. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169:867\u201373. https:\/\/doi.org\/10.1001\/archinternmed.2009.43.","journal-title":"Arch Intern Med"},{"key":"1019_CR67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2165\/11599090-000000000-00000","volume":"29","author":"JR Hutson","year":"2012","unstructured":"Hutson JR, Fischer HD, Wang X, Gruneir A, Daneman N, Gill SS, Rochon PA, Anderson GM. Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study. Drugs Aging. 2012;29:205\u201311. https:\/\/doi.org\/10.2165\/11599090-000000000-00000.","journal-title":"Drugs Aging"},{"key":"1019_CR68","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/jac\/dkw591","volume":"72","author":"JW Mason","year":"2017","unstructured":"Mason JW. Antimicrobials and QT prolongation. J Antimicrob Chemother. 2017;72:1272\u20134. https:\/\/doi.org\/10.1093\/jac\/dkw591.","journal-title":"J Antimicrob Chemother"},{"key":"1019_CR69","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1001\/jama.2014.4304","volume":"311","author":"EM Mortensen","year":"2014","unstructured":"Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, Johnson CS, Alvarez CA, Frei CR, Good C, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311:2199\u2013208. https:\/\/doi.org\/10.1001\/jama.2014.4304.","journal-title":"JAMA"},{"key":"1019_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/01.Jaa.0000511033.34198.95","volume":"30","author":"SS Sutton","year":"2017","unstructured":"Sutton SS. Is cardiovascular risk a concern when prescribing azithromycin? Jaapa. 2017;30:11\u20133. https:\/\/doi.org\/10.1097\/01.Jaa.0000511033.34198.95.","journal-title":"Jaapa."},{"key":"1019_CR71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejim.2015.09.009","volume":"28","author":"X Li","year":"2016","unstructured":"Li X, Wang M, Liu G, Ma J, Li C. Association of macrolides with overall mortality and cardiac death among patients with various infections: a meta-analysis. Eur J Intern Med. 2016;28:32\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2015.09.009.","journal-title":"Eur J Intern Med"},{"key":"1019_CR72","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jac\/dkw428","volume":"72","author":"B Darpo","year":"2017","unstructured":"Darpo B, Sager PT, Fernandes P, Jamieson BD, Keedy K, Zhou M, Oldach D. Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects. J Antimicrob Chemother. 2017;72:515\u201321. https:\/\/doi.org\/10.1093\/jac\/dkw428.","journal-title":"J Antimicrob Chemother"},{"key":"1019_CR73","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/cia.S133640","volume":"13","author":"A Giarratano","year":"2018","unstructured":"Giarratano A, Green SE, Nicolau DP. Review of antimicrobial use and considerations in the elderly population. Clin Interv Aging. 2018;13:657\u201367. https:\/\/doi.org\/10.2147\/cia.S133640.","journal-title":"Clin Interv Aging"},{"key":"1019_CR74","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/ki.1997.163","volume":"51","author":"D Fliser","year":"1997","unstructured":"Fliser D, Franek E, Joest M, Block S, Mutschler E, Ritz E. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int. 1997;51:1196\u2013204. https:\/\/doi.org\/10.1038\/ki.1997.163.","journal-title":"Kidney Int"},{"key":"1019_CR75","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0749-0690(18)30113-7","volume":"14","author":"LH Beck","year":"1998","unstructured":"Beck LH. Changes in renal function with aging. Clin Geriatr Med. 1998;14:199\u2013209.","journal-title":"Clin Geriatr Med"},{"key":"1019_CR76","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/(SICI)1097-0096(199805)26:4<185::AID-JCU1>3.0.CO;2-9","volume":"26","author":"D Miletic","year":"1998","unstructured":"Miletic D, Fuckar Z, Sustic A, Mozetic V, Stimac D, Zauhar G. Sonographic measurement of absolute and relative renal length in adults. J Clin Ultrasound. 1998;26:185\u20139. https:\/\/doi.org\/10.1002\/(SICI)1097-0096(199805)26:4%3c185::AID-JCU1%3e3.0.CO;2-9.","journal-title":"J Clin Ultrasound"},{"key":"1019_CR77","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1046\/j.1523-1755.2001.0590031052.x","volume":"59","author":"G Fuiano","year":"2001","unstructured":"Fuiano G, Sund S, Mazza G, Rosa M, Caglioti A, Gallo G, Natale G, Andreucci M, Memoli B, De Nicola L, et al. Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int. 2001;59:1052\u20138. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.0590031052.x.","journal-title":"Kidney Int"},{"key":"1019_CR78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1681\/ASN.V122385","volume":"12","author":"A Melk","year":"2001","unstructured":"Melk A, Halloran PF. Cell senescence and its implications for nephrology. J Am Soc Nephrol. 2001;12:385\u201393. https:\/\/doi.org\/10.1681\/ASN.V122385.","journal-title":"J Am Soc Nephrol"},{"key":"1019_CR79","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0272-6386(99)70046-6","volume":"34","author":"J Neugarten","year":"1999","unstructured":"Neugarten J, Gallo G, Silbiger S, Kasiske B. Glomerulosclerosis in aging humans is not influenced by gender. Am J Kidney Dis. 1999;34:884\u20138. https:\/\/doi.org\/10.1016\/S0272-6386(99)70046-6.","journal-title":"Am J Kidney Dis"},{"key":"1019_CR80","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/s0531-5565(03)00133-5","volume":"38","author":"K Turnheim","year":"2003","unstructured":"Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38:843\u201353. https:\/\/doi.org\/10.1016\/s0531-5565(03)00133-5.","journal-title":"Exp Gerontol"},{"key":"1019_CR81","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1172\/JCI102286","volume":"29","author":"DF Davies","year":"1950","unstructured":"Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29:496\u2013507. https:\/\/doi.org\/10.1172\/JCI102286.","journal-title":"J Clin Invest"},{"key":"1019_CR82","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000045389","volume":"82","author":"NK Hollenberg","year":"1999","unstructured":"Hollenberg NK, Rivera A, Meinking T, Martinez G, McCullough M, Passan D, Preston M, Taplin D, Vicaria-Clement M. Age, renal perfusion and function in island-dwelling indigenous Kuna Amerinds of Panama. Nephron. 1999;82:131\u20138. https:\/\/doi.org\/10.1159\/000045389.","journal-title":"Nephron"},{"key":"1019_CR83","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1053\/ajkd.2001.20628","volume":"37","author":"D Fliser","year":"2001","unstructured":"Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37:79\u201383. https:\/\/doi.org\/10.1053\/ajkd.2001.20628.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"1019_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000328010","volume":"119","author":"CG Musso","year":"2011","unstructured":"Musso CG, Oreopoulos DG. Aging and physiological changes of the kidneys including changes in glomerular filtration rate. Nephron Physiol. 2011;119(Suppl 1):1\u20135. https:\/\/doi.org\/10.1159\/000328010.","journal-title":"Nephron Physiol"},{"key":"1019_CR85","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00043426-200205000-00021","volume":"24","author":"JH Dalle","year":"2002","unstructured":"Dalle JH, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol. 2002;24:321\u20132. https:\/\/doi.org\/10.1097\/00043426-200205000-00021.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1019_CR86","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/s0749-0704(05)70367-5","volume":"13","author":"KL Wallace","year":"1997","unstructured":"Wallace KL. Antibiotic-induced convulsions. Crit Care Clin. 1997;13:741\u201362. https:\/\/doi.org\/10.1016\/s0749-0704(05)70367-5.","journal-title":"Crit Care Clin"},{"key":"1019_CR87","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/092986710790416326","volume":"17","author":"A Corsonello","year":"2010","unstructured":"Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17:571\u201384. https:\/\/doi.org\/10.2174\/092986710790416326.","journal-title":"Curr Med Chem"},{"key":"1019_CR88","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55:601\u20137. https:\/\/doi.org\/10.1093\/jac\/dki079.","journal-title":"J Antimicrob Chemother"},{"key":"1019_CR89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/157489108783413191","volume":"3","author":"AM Noreddin","year":"2008","unstructured":"Noreddin AM, El-Khatib W, Haynes V. Optimal dosing design for antibiotic therapy in the elderly: a pharmacokinetic and pharmacodynamic perspective. Recent Pat Antiinfect Drug Discov. 2008;3:45\u201352. https:\/\/doi.org\/10.2174\/157489108783413191.","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"1019_CR90","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00002512-200724040-00002","volume":"24","author":"AM Noreddin","year":"2007","unstructured":"Noreddin AM, Haynes V. Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly. Drugs Aging. 2007;24:275\u201392. https:\/\/doi.org\/10.2165\/00002512-200724040-00002.","journal-title":"Drugs Aging"},{"key":"1019_CR91","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.idc.2017.07.011","volume":"31","author":"JM Benson","year":"2017","unstructured":"Benson JM. Antimicrobial pharmacokinetics and pharmacodynamics in older adults. Infect Dis Clin. 2017;31:609\u201317. https:\/\/doi.org\/10.1016\/j.idc.2017.07.011.","journal-title":"Infect Dis Clin"},{"key":"1019_CR92","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jama.279.2.125","volume":"279","author":"SL Preston","year":"1998","unstructured":"Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:125\u20139. https:\/\/doi.org\/10.1001\/jama.279.2.125.","journal-title":"JAMA"},{"key":"1019_CR93","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/pharmaceutics13060833","volume":"13","author":"A Rodr\u00edguez-Gasc\u00f3n","year":"2021","unstructured":"Rodr\u00edguez-Gasc\u00f3n A, Solin\u00eds M\u00c1, Isla A. The role of PK\/PD analysis in the development and evaluation of antimicrobials. Pharmaceutics. 2021;13:833. https:\/\/doi.org\/10.3390\/pharmaceutics13060833.","journal-title":"Pharmaceutics"},{"key":"1019_CR94","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jac\/dkv428","volume":"71","author":"L Zhuang","year":"2016","unstructured":"Zhuang L, He Y, Xia H, Liu Y, Sy SK, Derendorf H. Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic\/pharmacodynamic model. J Antimicrob Chemother. 2016;71:1012\u201321. https:\/\/doi.org\/10.1093\/jac\/dkv428.","journal-title":"J Antimicrob Chemother"},{"key":"1019_CR95","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1046\/j.1198-743x.2001.00295.x","volume":"7","author":"MR Jacobs","year":"2001","unstructured":"Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589\u201396. https:\/\/doi.org\/10.1046\/j.1198-743x.2001.00295.x.","journal-title":"Clin Microbiol Infect"},{"key":"1019_CR96","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/antibiotics11080986","volume":"11","author":"LC Pereira","year":"2022","unstructured":"Pereira LC, F\u00e1tima MAD, Santos VV, Brand\u00e3o CM, Alves IA, Azeredo FJ. Pharmacokinetic\/pharmacodynamic modeling and application in antibacterial and antifungal pharmacotherapy: a narrative review. Antibiotics. 2022;11:986. https:\/\/doi.org\/10.3390\/antibiotics11080986.","journal-title":"Antibiotics"},{"key":"1019_CR97","doi-asserted-by":"publisher","unstructured":"Vacaroiu IA, Cuiban E, Geavlete BF, Gheorghita V, David C, Ene CV, Bulai C, Lupusoru GE, Lupusoru M, Balcangiu-Stroescu AE et al. Chronic kidney disease-an underestimated risk factor for antimicrobial resistance in patients with urinary tract infections. 2022;10: 2368. https:\/\/doi.org\/10.3390\/biomedicines10102368","DOI":"10.3390\/biomedicines10102368"},{"key":"1019_CR98","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41581-019-0150-7","volume":"15","author":"TZ Wang","year":"2019","unstructured":"Wang TZ, Kodiyanplakkal RPL, Calfee DP. Antimicrobial resistance in nephrology. Nat Rev Nephrol. 2019;15:463\u201381. https:\/\/doi.org\/10.1038\/s41581-019-0150-7.","journal-title":"Nat Rev Nephrol"},{"key":"1019_CR99","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.medmal.2019.06.010","volume":"50","author":"B Aloy","year":"2020","unstructured":"Aloy B, Launay-Vacher V, Bleibtreu A, Bortolotti P, Faure E, Filali A, Gauzit R, Gilbert M, Lesprit P, Mahieu R, et al. Antibiotics and chronic kidney disease: dose adjustment update for infectious disease clinical practice. Med Mal Infect. 2020;50:323\u201331. https:\/\/doi.org\/10.1016\/j.medmal.2019.06.010.","journal-title":"Med Mal Infect"},{"key":"1019_CR100","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2147\/IDR.S213183","volume":"12","author":"C-C Wu","year":"2019","unstructured":"Wu C-C, Tai C-H, Liao W-Y, Wang C-C, Kuo C-H, Lin S-W, Ku S-C. Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic\/pharmacodynamic target in Asian ICU population: a prospective observational study. Infect Drug Resist. 2019;12:2531\u201341. https:\/\/doi.org\/10.2147\/IDR.S213183.","journal-title":"Infect Drug Resist."},{"key":"1019_CR101","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jgar.2020.02.022","volume":"22","author":"M Falcone","year":"2020","unstructured":"Falcone M, Paul M, Tiseo G, Yahav D, Prendki V, Friberg LE, Guerri R, Gavazzi G, Mussini C, Tinelli M. Considerations for the optimal management of antibiotic therapy in elderly patients. J Glob Antimicrob Resist. 2020;22:325\u201333. https:\/\/doi.org\/10.1016\/j.jgar.2020.02.022.","journal-title":"J Glob Antimicrob Resist."},{"key":"1019_CR102","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coph.2015.06.006","volume":"24","author":"F Pea","year":"2015","unstructured":"Pea F. Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability. Curr Opin Pharmacol. 2015;24:18\u201322. https:\/\/doi.org\/10.1016\/j.coph.2015.06.006.","journal-title":"Curr Opin Pharmacol"},{"key":"1019_CR103","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","volume":"62","author":"MG Shlipak","year":"2013","unstructured":"Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis. 2013;62:595\u2013603. https:\/\/doi.org\/10.1053\/j.ajkd.2013.03.027.","journal-title":"Am J Kidney Dis"},{"issue":"485","key":"1019_CR104","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2017.01.019","volume":"23","author":"FV van Daalen","year":"2017","unstructured":"van Daalen FV, Prins JM, Opmeer BC, Boermeester MA, Visser CE, van Hest RM, Branger J, Mattsson E, van de Broek MFM, Roeleveld TC, et al. Effect of an antibiotic checklist on length of hospital stay and appropriate antibiotic use in adult patients treated with intravenous antibiotics: a stepped wedge cluster randomized trial. Clin Microbiol Infect. 2017;23(485):e1-485.e8. https:\/\/doi.org\/10.1016\/j.cmi.2017.01.019.","journal-title":"Clin Microbiol Infect"},{"key":"1019_CR105","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cmi.2020.11.032","volume":"27","author":"SL de Vroom","year":"2021","unstructured":"de Vroom SL, van Daalen FV, Zieck SE, Math\u00f4t RAA, van Hest RM, Geerlings SE. Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review. Clin Microbiol Infect. 2021;27:352\u201363. https:\/\/doi.org\/10.1016\/j.cmi.2020.11.032.","journal-title":"Clin Microbiol Infect"},{"key":"1019_CR106","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2215\/CJN.10710918","volume":"14","author":"L Bathini","year":"2019","unstructured":"Bathini L, Jandoc R, Kuwornu P, McArthur E, Weir MA, Sood MM, Battistella M, Muanda FT, Liu A, Jain AK, et al. Clinical outcomes of failing to dose-reduce cephalosporin antibiotics in older adults with CKD. Clin J Am Soc Nephrol. 2019;14:197. https:\/\/doi.org\/10.2215\/CJN.10710918.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1019_CR107","doi-asserted-by":"publisher","first-page":"e2224892","DOI":"10.1001\/jamanetworkopen.2022.24892","volume":"5","author":"FT Muanda","year":"2022","unstructured":"Muanda FT, Sood MM, Weir MA, Sontrop JM, Ahmadi F, Yoo E, Kim RB, Silverman MS, Knoll GA, Garg AX. Association of higher-dose fluoroquinolone therapy with serious adverse events in older adults with advanced chronic kidney disease. JAMA Netw Open. 2022;5:e2224892\u2013e2224892. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.24892.","journal-title":"JAMA Netw Open"},{"key":"1019_CR108","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02134-16","author":"PG Cojutti","year":"2017","unstructured":"Cojutti PG, Ramos-Martin V, Schiavon I, Rossi P, Baraldo M, Hope W, Pea F. Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.02134-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"1019_CR109","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3390\/ijerph19052516","volume":"19","author":"F Ebihara","year":"2022","unstructured":"Ebihara F, Hamada Y, Kato H, Maruyama T, Kimura T. Importance and reality of TDM for antibiotics not covered by insurance in Japan. Int J Environ Res Public Health. 2022;19:2516. https:\/\/doi.org\/10.3390\/ijerph19052516.","journal-title":"Int J Environ Res Public Health"},{"key":"1019_CR110","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12072-019-10004-1","volume":"14","author":"VC Patel","year":"2020","unstructured":"Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hep Int. 2020;14:24\u201334. https:\/\/doi.org\/10.1007\/s12072-019-10004-1.","journal-title":"Hep Int"},{"key":"1019_CR111","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/a-1765-0056","volume":"42","author":"CE Gallaher","year":"2022","unstructured":"Gallaher CE, Shawcross DL. Management of multidrug-resistant infections in cirrhosis. Semin Liver Dis. 2022;42:173\u201387. https:\/\/doi.org\/10.1055\/a-1765-0056.","journal-title":"Semin Liver Dis"},{"key":"1019_CR112","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1586\/17474124.2015.1100075","volume":"9","author":"J Fern\u00e1ndez","year":"2015","unstructured":"Fern\u00e1ndez J, Acevedo J. New antibiotic strategies in patients with cirrhosis and bacterial infection. Expert Rev Gastroenterol Hepatol. 2015;9:1495\u2013500. https:\/\/doi.org\/10.1586\/17474124.2015.1100075.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1019_CR113","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4254\/wjh.v4.i5.158","volume":"4","author":"C Bunchorntavakul","year":"2012","unstructured":"Bunchorntavakul C, Chavalitdhamrong D. Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol. 2012;4:158\u201368. https:\/\/doi.org\/10.4254\/wjh.v4.i5.158.","journal-title":"World J Hepatol"},{"key":"1019_CR114","doi-asserted-by":"publisher","first-page":"5556354","DOI":"10.1155\/2021\/5556354","volume":"2021","author":"A Adenote","year":"2021","unstructured":"Adenote A, Dumic I, Madrid C, Barusya C, Nordstrom CW, Rueda Prada L. NAFLD and infection, a nuanced relationship. Can J Gastroenterol Hepatol. 2021;2021:5556354. https:\/\/doi.org\/10.1155\/2021\/5556354.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1019_CR115","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/antibiotics11010031","volume":"11","author":"C Zoratti","year":"2021","unstructured":"Zoratti C, Moretti R, Rebuzzi L, Albergati IV, Di Somma A, Decorti G, Di Bella S, Croc\u00e8 LS, Giuffr\u00e8 M. Antibiotics and liver cirrhosis: what the physicians need to know. Antibiotics (Basel, Switzerland). 2021;11:31. https:\/\/doi.org\/10.3390\/antibiotics11010031.","journal-title":"Antibiotics (Basel, Switzerland)."},{"key":"1019_CR116","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/14787210.2020.1725473","volume":"18","author":"AE Maraolo","year":"2020","unstructured":"Maraolo AE, Scotto R, Zappulo E, Pinchera B, Schiano Moriello N, Nappa S, Buonomo AR, Gentile I. Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Rev Anti Infect Ther. 2020;18:191\u2013202. https:\/\/doi.org\/10.1080\/14787210.2020.1725473.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1019_CR117","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.3390\/ijms22094496","volume":"22","author":"CJ Wiedermann","year":"2021","unstructured":"Wiedermann CJ. Hypoalbuminemia as surrogate and culprit of infections. Int J Mol Sci. 2021;22:4496. https:\/\/doi.org\/10.3390\/ijms22094496.","journal-title":"Int J Mol Sci"},{"key":"1019_CR118","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","volume":"50","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99\u2013110. https:\/\/doi.org\/10.2165\/11539220-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1019_CR119","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2146\/ajhp140031","volume":"71","author":"J Halilovic","year":"2014","unstructured":"Halilovic J, Heintz BH. Antibiotic dosing in cirrhosis. Am J Health Syst Pharm. 2014;71:1621\u201334. https:\/\/doi.org\/10.2146\/ajhp140031.","journal-title":"Am J Health Syst Pharm"},{"key":"1019_CR120","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1128\/AAC.01430-08","volume":"53","author":"JFP Oliveira","year":"2009","unstructured":"Oliveira JFP, Silva CA, Barbieri CD, Oliveira GM, Zanetta DMT, Burdmann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53:2887\u201391. https:\/\/doi.org\/10.1128\/AAC.01430-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"1019_CR121","unstructured":"US FDA. Amoxicillin (Amoxil) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050542s24,050754s11,050760s10,050761s10lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR122","unstructured":"US FDA. Ampicillin\/sulbactam (Unasyn) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050608s029lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR123","unstructured":"US FDA. Ciprofloxacin (Cipro IV) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019857s062lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR124","unstructured":"US FDA. Ciprofloxacin (Cipro) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019537s086lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR125","unstructured":"US FDA. Levofloxacin (Levaquin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021721s020_020635s57_020634s52_lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR126","unstructured":"US FDA. Moxifloxacin (Avelox) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021085s063lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR127","unstructured":"US FDA. Linezolid (Zyvox) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021130s032,021131s026,021132s031lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR128","unstructured":"US FDA. Azithromycin (Zitromax) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050710s039,050711s036,050784s023lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR129","unstructured":"US FDA. Clarithromycin (Biaxin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050662s042,050698s024,050775s013lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR130","unstructured":"US Food and Drug Administration. Erythromycin (Ery-Ped) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/050207s074,050611s036lbl.pdf. Accessed 20 Feb 2023."},{"key":"1019_CR131","unstructured":"US FDA. Erythromycin (Erithrocin) [package insert]. https:\/\/www.nebraskamed.com\/sites\/default\/files\/documents\/for-providers\/asp\/tnmc-anti-infective-renal-dosing-guidelines.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR132","unstructured":"US FDA. Metronidazole (Metronidazole) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/018890s052lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR133","unstructured":"US FDA. Rifampin (Rifadin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050420s073,050627s012lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR134","unstructured":"US FDA. Tetracycline (Tetracycline) [package insert]. https:\/\/www.nebraskamed.com\/sites\/default\/files\/documents\/for-providers\/asp\/tnmc-anti-infective-renal-dosing-guidelines.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR135","unstructured":"US FDA. Doxycycline (Doryx) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050795s005lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR136","unstructured":"US FDA. Doxycyline (Vibramycin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050442s016lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR137","unstructured":"US FDA.Minocycline (Minocin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050649023lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR138","unstructured":"US FDA. Tigecycline (Tigacyl) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021821s021lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR139","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14740338.2017.1270264","volume":"16","author":"I Kyriakidis","year":"2017","unstructured":"Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16:149\u201365. https:\/\/doi.org\/10.1080\/14740338.2017.1270264.","journal-title":"Expert Opin Drug Saf"},{"key":"1019_CR140","doi-asserted-by":"publisher","first-page":"i26","DOI":"10.1093\/jac\/dkx446","volume":"73","author":"A Mourad","year":"2018","unstructured":"Mourad A, Perfect JR. Tolerability profile of the current antifungal armoury. J Antimicrob Chemother. 2018;73:i26\u201332. https:\/\/doi.org\/10.1093\/jac\/dkx446.","journal-title":"J Antimicrob Chemother"},{"key":"1019_CR141","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40266-018-0576-9","volume":"35","author":"BGJ Dekkers","year":"2018","unstructured":"Dekkers BGJ, Veringa A, Marriott DJE, Boonstra JM, van der Elst KCM, Doukas FF, McLachlan AJ, Alffenaar J-WC. Invasive candidiasis in the elderly: considerations for drug therapy. Drugs Aging. 2018;35:781\u20139. https:\/\/doi.org\/10.1007\/s40266-018-0576-9.","journal-title":"Drugs Aging"},{"key":"1019_CR142","unstructured":"US FDA. Sulfamethoxazole and trimethoprim (Bactrim) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/017377s068s073lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR143","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/archinternmed.2010.142","volume":"170","author":"T Antoniou","year":"2010","unstructured":"Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170:1045\u20139. https:\/\/doi.org\/10.1001\/archinternmed.2010.142.","journal-title":"Arch Intern Med"},{"key":"1019_CR144","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1365-2125.2010.03866.x","volume":"71","author":"T Antoniou","year":"2011","unstructured":"Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Trimethoprim\/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. Br J Clin Pharmacol. 2011;71:544\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03866.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1019_CR145","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/gerona\/glu072","volume":"70","author":"A Tan","year":"2014","unstructured":"Tan A, Holmes HM, Kuo Y-F, Raji MA, Goodwin JS. Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use. J Gerontol Ser A. 2014;70:247\u201354. https:\/\/doi.org\/10.1093\/gerona\/glu072.","journal-title":"J Gerontol Ser A"},{"key":"1019_CR146","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.amjmed.2011.08.014","volume":"125","author":"J Baillargeon","year":"2012","unstructured":"Baillargeon J, Holmes HM, Lin Y-L, Raji MA, Sharma G, Kuo Y-F. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012;125:183\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2011.08.014.","journal-title":"Am J Med"},{"key":"1019_CR147","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"SH Chang","year":"2017","unstructured":"Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, See LC, Kuo CF. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318:1250\u20139. https:\/\/doi.org\/10.1001\/jama.2017.13883.","journal-title":"JAMA"},{"key":"1019_CR148","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1055\/s-0034-1381233","volume":"40","author":"G Lippi","year":"2014","unstructured":"Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost. 2014;40:756\u201365. https:\/\/doi.org\/10.1055\/s-0034-1381233.","journal-title":"Semin Thromb Hemost"},{"key":"1019_CR149","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40263-017-0427-y","volume":"31","author":"C Parsons","year":"2017","unstructured":"Parsons C, van der Steen JT. Antimicrobial use in patients with dementia: current concerns and future recommendations. CNS Drugs. 2017;31:433\u20138. https:\/\/doi.org\/10.1007\/s40263-017-0427-y.","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"1019_CR150","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.injury.2020.02.009","volume":"51","author":"A Delgado","year":"2020","unstructured":"Delgado A, Cordero GGE, Marcos S, Cordero-Ampuero J. Influence of cognitive impairment on mortality, complications and functional outcome after hip fracture: dementia as a risk factor for sepsis and urinary infection. Injury. 2020;51(Suppl 1):S19-s24. https:\/\/doi.org\/10.1016\/j.injury.2020.02.009.","journal-title":"Injury"},{"key":"1019_CR151","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000367783","volume":"39","author":"NC Foley","year":"2015","unstructured":"Foley NC, Affoo RH, Martin RE. A systematic review and meta-analysis examining pneumonia-associated mortality in dementia. Dement Geriatr Cogn Disord. 2015;39:52\u201367. https:\/\/doi.org\/10.1159\/000367783.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1019_CR152","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00406-020-01205-z","volume":"271","author":"TI Hariyanto","year":"2021","unstructured":"Hariyanto TI, Putri C, Situmeang RFV, Kurniawan A. Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection. Eur Arch Psychiatry Clin Neurosci. 2021;271:393\u20135. https:\/\/doi.org\/10.1007\/s00406-020-01205-z.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1019_CR153","doi-asserted-by":"publisher","first-page":"5197","DOI":"10.1038\/s41598-022-09222-9","volume":"12","author":"J Komagamine","year":"2022","unstructured":"Komagamine J, Yabuki T, Noritomi D, Okabe T. Prevalence of and factors associated with atypical presentation in bacteremic urinary tract infection. Sci Rep. 2022;12:5197\u20135197. https:\/\/doi.org\/10.1038\/s41598-022-09222-9.","journal-title":"Sci Rep"},{"key":"1019_CR154","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1164\/rccm.201212-2154OC","volume":"188","author":"FA Shah","year":"2013","unstructured":"Shah FA, Pike F, Alvarez K, Angus D, Newman AB, Lopez O, Tate J, Kapur V, Wilsdon A, Krishnan JA, et al. Bidirectional relationship between cognitive function and pneumonia. Am J Respir Crit Care Med. 2013;188:586\u201392. https:\/\/doi.org\/10.1164\/rccm.201212-2154OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1019_CR155","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3233\/jpd-213103","volume":"12","author":"E Hogg","year":"2022","unstructured":"Hogg E, Frank S, Oft J, Benway B, Rashid MH, Lahiri S. Urinary tract infection in Parkinson\u2019s disease. J Parkinsons Dis. 2022;12:743\u201357. https:\/\/doi.org\/10.3233\/jpd-213103.","journal-title":"J Parkinsons Dis"},{"key":"1019_CR156","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2147\/CIA.S162701","volume":"13","author":"A Chudiak","year":"2018","unstructured":"Chudiak A, Uchmanowicz I, Mazur G. Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging. 2018;13:1409\u201318. https:\/\/doi.org\/10.2147\/CIA.S162701.","journal-title":"Clin Interv Aging"},{"key":"1019_CR157","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223997","volume":"14","author":"D Rohde","year":"2019","unstructured":"Rohde D, Gaynor E, Large M, Mellon L, Bennett K, Williams DJ, Brewer L, Hall P, Callaly E, Dolan E, et al. Cognitive impairment and medication adherence post-stroke: a five-year follow-up of the ASPIRE-S cohort. PLoS ONE. 2019;14: e0223997. https:\/\/doi.org\/10.1371\/journal.pone.0223997.","journal-title":"PLoS ONE"},{"key":"1019_CR158","doi-asserted-by":"publisher","first-page":"11688","DOI":"10.1038\/s41598-018-29974-7","volume":"8","author":"MH Cho","year":"2018","unstructured":"Cho MH, Shin DW, Chang SA, Lee JE, Jeong SM, Kim SH, Yun JM, Son K. Association between cognitive impairment and poor antihypertensive medication adherence in elderly hypertensive patients without dementia. Sci Rep. 2018;8:11688. https:\/\/doi.org\/10.1038\/s41598-018-29974-7.","journal-title":"Sci Rep"},{"key":"1019_CR159","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4065\/mcp.2010.0639","volume":"86","author":"S Leekha","year":"2011","unstructured":"Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc. 2011;86:156\u201367. https:\/\/doi.org\/10.4065\/mcp.2010.0639.","journal-title":"Mayo Clin Proc"},{"key":"1019_CR160","doi-asserted-by":"publisher","first-page":"207","DOI":"10.9740\/mhc.2016.07.207","volume":"6","author":"A Warstler","year":"2016","unstructured":"Warstler A, Bean J. Antimicrobial-induced cognitive side effects. Mental Health Clin. 2016;6:207\u201314. https:\/\/doi.org\/10.9740\/mhc.2016.07.207.","journal-title":"Mental Health Clin."},{"key":"1019_CR161","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jac\/27.4.405","volume":"27","author":"SE Schliamser","year":"1991","unstructured":"Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother. 1991;27:405\u201325. https:\/\/doi.org\/10.1093\/jac\/27.4.405.","journal-title":"J Antimicrob Chemother"},{"key":"1019_CR162","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/nu13020389","volume":"13","author":"T Karakan","year":"2021","unstructured":"Karakan T, Ozkul C, K\u00fcpeli Akkol E, Bilici S, Sobarzo-S\u00e1nchez E, Capasso R. Gut-brain-microbiota axis: antibiotics and functional gastrointestinal disorders. Nutrients. 2021;13:389. https:\/\/doi.org\/10.3390\/nu13020389.","journal-title":"Nutrients"},{"key":"1019_CR163","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/gutjnl-2016-312297","volume":"65","author":"G Ianiro","year":"2016","unstructured":"Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65:1906\u201315. https:\/\/doi.org\/10.1136\/gutjnl-2016-312297.","journal-title":"Gut"},{"key":"1019_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.564271","volume":"11","author":"KE Lee","year":"2020","unstructured":"Lee KE, Kim JK, Kim DH. Orally administered antibiotics vancomycin and ampicillin cause cognitive impairment with gut dysbiosis in mice with transient global forebrain ischemia. Front Microbiol. 2020;11: 564271. https:\/\/doi.org\/10.3389\/fmicb.2020.564271.","journal-title":"Front Microbiol"},{"key":"1019_CR165","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbi.2016.02.020","volume":"56","author":"EE Fr\u00f6hlich","year":"2016","unstructured":"Fr\u00f6hlich EE, Farzi A, Mayerhofer R, Reichmann F, Ja\u010dan A, Wagner B, Zinser E, Bordag N, Magnes C, Fr\u00f6hlich E, et al. Cognitive impairment by antibiotic-induced gut dysbiosis: analysis of gut microbiota-brain communication. Brain Behav Immun. 2016;56:140\u201355. https:\/\/doi.org\/10.1016\/j.bbi.2016.02.020.","journal-title":"Brain Behav Immun"},{"key":"1019_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.888333","volume":"13","author":"M Kim","year":"2022","unstructured":"Kim M, Park SJ, Choi S, Chang J, Kim SM, Jeong S, Park YJ, Lee G, Son JS, Ahn JC, et al. Association between antibiotics and dementia risk: a retrospective cohort study. Front Pharmacol. 2022;13: 888333. https:\/\/doi.org\/10.3389\/fphar.2022.888333.","journal-title":"Front Pharmacol"},{"key":"1019_CR167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264649","volume":"17","author":"RS Mehta","year":"2022","unstructured":"Mehta RS, Lochhead P, Wang Y, Ma W, Nguyen LH, Kochar B, Huttenhower C, Grodstein F, Chan AT. Association of midlife antibiotic use with subsequent cognitive function in women. PLoS ONE. 2022;17: e0264649. https:\/\/doi.org\/10.1371\/journal.pone.0264649.","journal-title":"PLoS ONE"},{"key":"1019_CR168","doi-asserted-by":"publisher","unstructured":"Molloy DW, Standish TI, Zhou Q, Guyatt G, Group TDS. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial. 2013;28:463\u2013470. https:\/\/doi.org\/10.1002\/gps.3846.","DOI":"10.1002\/gps.3846"},{"key":"1019_CR169","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40263-019-00649-9","volume":"33","author":"MK Bangert","year":"2019","unstructured":"Bangert MK, Hasbun R. Neurological and psychiatric adverse effects of antimicrobials. CNS Drugs. 2019;33:727\u201353. https:\/\/doi.org\/10.1007\/s40263-019-00649-9.","journal-title":"CNS Drugs"},{"key":"1019_CR170","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/00002512-199710040-00003","volume":"10","author":"K M\u00f6rike","year":"1997","unstructured":"M\u00f6rike K, Schwab M, Klotz U. Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging. 1997;10:259\u201377. https:\/\/doi.org\/10.2165\/00002512-199710040-00003.","journal-title":"Drugs Aging"},{"key":"1019_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40266-014-0232-y","volume":"32","author":"F Mizokami","year":"2015","unstructured":"Mizokami F, Mizuno T. Acute kidney injury induced by antimicrobial agents in the elderly: awareness and mitigation strategies. Drugs Aging. 2015;32:1\u201312. https:\/\/doi.org\/10.1007\/s40266-014-0232-y.","journal-title":"Drugs Aging"},{"key":"1019_CR172","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.clinthera.2014.09.020","volume":"36","author":"A Mattappalil","year":"2014","unstructured":"Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther. 2014;36:1489-1511.e4. https:\/\/doi.org\/10.1016\/j.clinthera.2014.09.020.","journal-title":"Clin Ther"},{"key":"1019_CR173","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40266-017-0484-4","volume":"34","author":"S Khan","year":"2017","unstructured":"Khan S, Loi V, Rosner MH. Drug-induced kidney injury in the elderly. Drugs Aging. 2017;34:729\u201341. https:\/\/doi.org\/10.1007\/s40266-017-0484-4.","journal-title":"Drugs Aging"},{"key":"1019_CR174","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12877-021-02512-3","volume":"21","author":"T Chinzowu","year":"2021","unstructured":"Chinzowu T, Roy S, Nishtala PS. Risk of antimicrobial-associated organ injury among the older adults: a systematic review and meta-analysis. BMC Geriatr. 2021;21:617. https:\/\/doi.org\/10.1186\/s12877-021-02512-3.","journal-title":"BMC Geriatr"},{"key":"1019_CR175","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1086\/428125","volume":"40","author":"CM Faulkner","year":"2005","unstructured":"Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005;40:997\u20131004. https:\/\/doi.org\/10.1086\/428125.","journal-title":"Clin Infect Dis"},{"key":"1019_CR176","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40266-020-00786-7","volume":"37","author":"MN Al-Hasan","year":"2020","unstructured":"Al-Hasan MN, Al-Jaghbeer MJ. Use of antibiotics in chronic obstructive pulmonary disease: what is their current role in older patients? Drugs Aging. 2020;37:627\u201333. https:\/\/doi.org\/10.1007\/s40266-020-00786-7.","journal-title":"Drugs Aging"},{"key":"1019_CR177","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/0897190013516503","volume":"27","author":"NM Maisch","year":"2014","unstructured":"Maisch NM, Kochupurackal JG, Sin J. Azithromycin and the risk of cardiovascular complications. J Pharm Pract. 2014;27:496\u2013500. https:\/\/doi.org\/10.1177\/0897190013516503.","journal-title":"J Pharm Pract"},{"key":"1019_CR178","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bcpt.13679","volume":"130","author":"T Hirai","year":"2022","unstructured":"Hirai T, Hosohata K, Ogawa Y, Iwamoto T. Clinical predictors of nephrotoxicity associated with teicoplanin: meta-analysis and meta-regression. Basic Clin Pharmacol Toxicol. 2022;130:110\u201321. https:\/\/doi.org\/10.1111\/bcpt.13679.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1019_CR179","volume-title":"Daptomycin","author":"S Patel","year":"2022","unstructured":"Patel S, Saw S. Daptomycin. Treasure Island: StatPearls Publishing; 2022."},{"key":"1019_CR180","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jama.2018.19283","volume":"321","author":"ES Shenoy","year":"2019","unstructured":"Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321:188\u201399. https:\/\/doi.org\/10.1001\/jama.2018.19283.","journal-title":"JAMA"},{"key":"1019_CR181","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/14740338.2018.1462334","volume":"17","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Kalimeris GD, Triarides NA, Falagas ME. An update on adverse drug reactions related to \u03b2-lactam antibiotics. Expert Opin Drug Saf. 2018;17:499\u2013508. https:\/\/doi.org\/10.1080\/14740338.2018.1462334.","journal-title":"Expert Opin Drug Saf"},{"key":"1019_CR182","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1517\/14740338.2012.643866","volume":"11","author":"P Lagac\u00e9-Wiens","year":"2012","unstructured":"Lagac\u00e9-Wiens P, Rubinstein E. Adverse reactions to \u03b2-lactam antimicrobials. Expert Opin Drug Saf. 2012;11:381\u201399. https:\/\/doi.org\/10.1517\/14740338.2012.643866.","journal-title":"Expert Opin Drug Saf"},{"key":"1019_CR183","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/cid\/ciy149","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:987\u201394. https:\/\/doi.org\/10.1093\/cid\/ciy149.","journal-title":"Clin Infect Dis"},{"key":"1019_CR184","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/s2468-1253(20)30006-6","volume":"5","author":"MI Lucena","year":"2020","unstructured":"Lucena MI, Sanabria J, Garc\u00eda-Cortes M, Stephens C, Andrade RJ. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020;5:862\u201374. https:\/\/doi.org\/10.1016\/s2468-1253(20)30006-6.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1019_CR185","doi-asserted-by":"publisher","first-page":"ofz508","DOI":"10.1093\/ofid\/ofz508","volume":"6","author":"N Wang","year":"2019","unstructured":"Wang N, Nguyen PK, Pham CU, Smith EA, Kim B, Goetz MB, Graber CJ. Sodium Content of intravenous antibiotic preparations. Open forum Infect Dis. 2019;6:ofz508. https:\/\/doi.org\/10.1093\/ofid\/ofz508.","journal-title":"Open forum Infect Dis"},{"key":"1019_CR186","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40264-017-0578-2","volume":"40","author":"S Deshayes","year":"2017","unstructured":"Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to \u03b2-lactam antibiotics: a literature review. Drug Saf. 2017;40:1171\u201398. https:\/\/doi.org\/10.1007\/s40264-017-0578-2.","journal-title":"Drug Saf"},{"key":"1019_CR187","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40261-017-0498-z","volume":"37","author":"N Zareifopoulos","year":"2017","unstructured":"Zareifopoulos N, Panayiotakopoulos G. Neuropsychiatric effects of antimicrobial agents. Clin Drug Investig. 2017;37:423\u201337. https:\/\/doi.org\/10.1007\/s40261-017-0498-z.","journal-title":"Clin Drug Investig"},{"key":"1019_CR188","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","volume":"21","author":"LE Payne","year":"2017","unstructured":"Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21:276. https:\/\/doi.org\/10.1186\/s13054-017-1856-1.","journal-title":"Crit Care"},{"key":"1019_CR189","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","volume":"27","author":"R Stahlmann","year":"2010","unstructured":"Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27:193\u2013209. https:\/\/doi.org\/10.2165\/11531490-000000000-00000.","journal-title":"Drugs Aging"},{"key":"1019_CR190","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00228-019-02713-1","volume":"75","author":"C Alves","year":"2019","unstructured":"Alves C, Mendes D, Marques FB. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2019;75:1431\u201343. https:\/\/doi.org\/10.1007\/s00228-019-02713-1.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7662","key":"1019_CR191","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bmj.a816","volume":"337","author":"JH Tanne","year":"2008","unstructured":"Tanne JH. FDA adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics. Br Med J. 2008;337(7662):816. https:\/\/doi.org\/10.1136\/bmj.a816.","journal-title":"Br Med J"},{"key":"1019_CR192","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1086\/322685","volume":"33","author":"CA Kauffman","year":"2001","unstructured":"Kauffman CA. Fungal infections in older adults. Clin Infect Dis. 2001;33:550\u20135. https:\/\/doi.org\/10.1086\/322685.","journal-title":"Clin Infect Dis"},{"key":"1019_CR193","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/cid\/cis290","volume":"54","author":"S Mistro","year":"2012","unstructured":"Mistro S, Maciel IDM, de Menezes RG, Maia ZP, Schooley RT, Badar\u00f3 R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012;54:1774\u20137. https:\/\/doi.org\/10.1093\/cid\/cis290.","journal-title":"Clin Infect Dis"},{"key":"1019_CR194","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jcpt.12237","volume":"40","author":"JR Soares","year":"2015","unstructured":"Soares JR, Nunes MC, Leite AF, Falqueto EB, Lacerda BE, Ferrari TC. Reversible dilated cardiomyopathy associated with amphotericin B therapy. J Clin Pharm Ther. 2015;40:333\u20135. https:\/\/doi.org\/10.1111\/jcpt.12237.","journal-title":"J Clin Pharm Ther"},{"key":"1019_CR195","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11894-012-0299-8","volume":"15","author":"JG Stine","year":"2013","unstructured":"Stine JG, Sateesh P, Lewis JH. Drug-induced liver injury in the elderly. Curr Gastroenterol Rep. 2013;15:299. https:\/\/doi.org\/10.1007\/s11894-012-0299-8.","journal-title":"Curr Gastroenterol Rep"},{"key":"1019_CR196","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.tube.2014.10.006","volume":"95","author":"JD Hosford","year":"2015","unstructured":"Hosford JD, von Fricken ME, Lauzardo M, Chang M, Dai Y, Lyon JA, Shuster J, Fennelly KP. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis (Edinb). 2015;95:112\u201322. https:\/\/doi.org\/10.1016\/j.tube.2014.10.006.","journal-title":"Tuberculosis (Edinb)"},{"key":"1019_CR197","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2165\/11534340-000000000-00000","volume":"24","author":"JS Kass","year":"2010","unstructured":"Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs. 2010;24:655\u201367. https:\/\/doi.org\/10.2165\/11534340-000000000-00000.","journal-title":"CNS Drugs"},{"key":"1019_CR198","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0891-5520(20)30202-6","volume":"2","author":"WL Drew","year":"1988","unstructured":"Drew WL, Buhles W, Erlich KS. Herpesvirus infections (cytomegalovirus, herpes simplex virus, varicella-zoster virus). How to use ganciclovir (DHPG) and acyclovir. Infect Dis Clin N Am. 1988;2:495\u2013509.","journal-title":"Infect Dis Clin N Am."},{"key":"1019_CR199","unstructured":"US FDA. Zovirax (Aciclovyr) [package insert]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/018828s030,020089s019,019909s020lbl.pdf. Accessed 1 Sep 2022."},{"key":"1019_CR200","doi-asserted-by":"publisher","unstructured":"Brandariz-Nu\u00f1ez D, Correas-Sanahuja M, Maya-Gallego S, Mart\u00edn Herranz I. Neurotoxicity associated with acyclovir and valacyclovir: a systematic review of cases. 2021;46:918\u201326. https:\/\/doi.org\/10.1111\/jcpt.13464","DOI":"10.1111\/jcpt.13464"},{"key":"1019_CR201","unstructured":"US FDA. Ganciclovir (Ganciclovir) [package insert]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209347lbl.pdf. Accessed 1 Sep 2022."},{"key":"1019_CR202","unstructured":"US FDA. Remdesivir (Veklury) [package insert]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214787Orig1s000lbl.pdf. Accessed 1 Sep 2022."},{"key":"1019_CR203","unstructured":"European Medicines Agency. Molnupiravir (Lagevrio) [package insert]. www.ema.europa.eu\/en\/documents\/referral\/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-conditions-use-conditions_en.pdf. Accessed 1 Sep 2022."},{"key":"1019_CR204","unstructured":"US FDA. Foscarnet (Foscavir) [package insert]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020068s018lbl.pdf. Accessed 1 Sep 2022."},{"key":"1019_CR205","unstructured":"US FDA. Oseltamivir (Tamiflu) [package insert]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021087s057lbl.pdf. Accessed 1 Sep 2022."},{"key":"1019_CR206","unstructured":"Electronic Medicines Compendium. Zanamivir (Ralenza) [package insert]. www.medicines.org.uk\/emc\/product\/3809\/smpc. Accessed 1 Sep 2022."},{"key":"1019_CR207","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","volume":"27","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423\u201331. https:\/\/doi.org\/10.1007\/s11096-005-1319-7.","journal-title":"Pharm World Sci"},{"key":"1019_CR208","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.2147\/dddt.S259058","volume":"14","author":"L Li","year":"2020","unstructured":"Li L, Wang X, Wang R, Hu Y, Jiang S, Lu X. Antiviral Agent therapy optimization in special populations of COVID-19 patients. Drug Des Devel Ther. 2020;14:3001\u201313. https:\/\/doi.org\/10.2147\/dddt.S259058.","journal-title":"Drug Des Devel Ther."},{"key":"1019_CR209","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/phar.1670","volume":"35","author":"J Jourjy","year":"2015","unstructured":"Jourjy J, Dahl K, Huesgen E. Antiretroviral treatment efficacy and safety in older HIV-infected adults. Pharmacotherapy. 2015;35:1140\u201351. https:\/\/doi.org\/10.1002\/phar.1670.","journal-title":"Pharmacotherapy"},{"key":"1019_CR210","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4254\/wjh.v9.i5.227","volume":"9","author":"B Kayaaslan","year":"2017","unstructured":"Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017;9:227\u201341. https:\/\/doi.org\/10.4254\/wjh.v9.i5.227.","journal-title":"World J Hepatol"},{"key":"1019_CR211","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071687","author":"AM Benedicto","year":"2021","unstructured":"Benedicto AM, Fuster-Mart\u00ednez I, Tosca J, Esplugues JV, Blas-Garc\u00eda A, Apostolova N. NNRTI and liver damage: evidence of their association and the mechanisms involved. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10071687.","journal-title":"Cells"},{"key":"1019_CR212","unstructured":"US FDA. Epavirenz (Sustiva) [package insert]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020972s038lbl.pdf. Accessed 1 Sep 2022."},{"key":"1019_CR213","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jinf.2010.06.002","volume":"61","author":"S Tsiodras","year":"2010","unstructured":"Tsiodras S, Perelas A, Wanke C, Mantzoros CS. The HIV-1\/HAART associated metabolic syndrome\u2014novel adipokines, molecular associations and therapeutic implications. J Infect. 2010;61:101\u201313. https:\/\/doi.org\/10.1016\/j.jinf.2010.06.002.","journal-title":"J Infect"},{"key":"1019_CR214","unstructured":"US FDA. Ritonavir (Norvir) [package insert]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209512lbl.pdf. Accessed 1 Sep 2022."},{"key":"1019_CR215","doi-asserted-by":"publisher","first-page":"i2","DOI":"10.1093\/jac\/dkac211","volume":"77","author":"R Cant\u00f3n","year":"2022","unstructured":"Cant\u00f3n R, Akova M, Langfeld K, Torumkuney D. Relevance of the consensus principles for appropriate antibiotic prescribing in 2022. J Antimicrob Chemother. 2022;77:i2\u20139. https:\/\/doi.org\/10.1093\/jac\/dkac211.","journal-title":"J Antimicrob Chemother"},{"key":"1019_CR216","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.cegh.2018.12.005","volume":"7","author":"D Chandrasekhar","year":"2019","unstructured":"Chandrasekhar D, Manaparambil H, Parambil JC. Outcome assessment of intervention on appropriateness of antibiotic use among geriatric patients: a prospective interventional study from a tertiary care referral hospital. Clin Epidemiol Global Health. 2019;7:536\u201341. https:\/\/doi.org\/10.1016\/j.cegh.2018.12.005.","journal-title":"Clin Epidemiol Global Health."},{"key":"1019_CR217","doi-asserted-by":"publisher","first-page":"18884","DOI":"10.1038\/s41598-021-98431-9","volume":"11","author":"MR Cantudo-Cuenca","year":"2021","unstructured":"Cantudo-Cuenca MR, Jimenez-Morales A, Mart\u00ednez-de la Plata JE. Pharmacist-driven antimicrobial stewardship program in a long-term care facility by assessment of appropriateness. Sci Rep. 2021;11:18884\u201318884. https:\/\/doi.org\/10.1038\/s41598-021-98431-9.","journal-title":"Sci Rep"},{"key":"1019_CR218","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s1473-3099(20)30477-1","volume":"21","author":"SS Kadri","year":"2021","unstructured":"Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21:241\u201351. https:\/\/doi.org\/10.1016\/s1473-3099(20)30477-1.","journal-title":"Lancet Infect Dis"},{"key":"1019_CR219","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1525-1497.2001.016006376.x","volume":"16","author":"M Loeb","year":"2001","unstructured":"Loeb M, Simor AE, Landry L, Walter S, McArthur M, Duffy J, et al. Antibiotic use in Ontario facilities that provide chronic care. J Gen Intern Med. 2001;16:376\u201383. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016006376.x.","journal-title":"J Gen Intern Med"},{"key":"1019_CR220","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.2007","volume":"4","author":"SS Magill","year":"2021","unstructured":"Magill SS, O\u2019Leary E, Ray SM, Kainer MA, Evans C, Bamberg WM, et al. Assessment of the appropriateness of antimicrobial use in US hospitals. JAMA Netw Open. 2021;4: e212007. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.2007.","journal-title":"JAMA Netw Open"},{"key":"1019_CR221","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jamda.2021.11.010","volume":"23","author":"JJS Rutten","year":"2022","unstructured":"Rutten JJS, van Buul LW, Smalbrugge M, Geerlings SE, Gerritsen DL, Natsch S, et al. An electronic health record integrated decision tool and supportive interventions to improve antibiotic prescribing for urinary tract infections in nursing homes: a cluster randomized controlled trial. J Am Med Dir Assoc. 2022;23:387\u201393. https:\/\/doi.org\/10.1016\/j.jamda.2021.11.010.","journal-title":"J Am Med Dir Assoc"},{"key":"1019_CR222","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/antibiotics10121484","volume":"10","author":"A Saatchi","year":"2021","unstructured":"Saatchi A, Reid JN, Povitz M, Shariff SZ, Silverman M, Morris AM, et al. Appropriateness of outpatient antibiotic use in seniors across two Canadian provinces. Antibiotics (Basel, Switzerland). 2021;10:1484. https:\/\/doi.org\/10.3390\/antibiotics10121484.","journal-title":"Antibiotics (Basel, Switzerland)."},{"key":"1019_CR223","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.clinthera.2008.06.009","volume":"30","author":"CC Tobia","year":"2008","unstructured":"Tobia CC, Aspinall SL, Good CB, Fine MJ, Hanlon JT. Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: a cross-sectional study. Clin Ther. 2008;30:1135\u201344. https:\/\/doi.org\/10.1016\/j.clinthera.2008.06.009.","journal-title":"Clin Ther"},{"key":"1019_CR224","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jamda.2014.10.003","volume":"16","author":"LW van Buul","year":"2015","unstructured":"van Buul LW, Veenhuizen RB, Achterberg WP, Schellevis FG, Essink RT, de Greeff SC, et al. Antibiotic prescribing in Dutch nursing homes: how appropriate is it? J Am Med Dir Assoc. 2015;16:229\u201337. https:\/\/doi.org\/10.1016\/j.jamda.2014.10.003.","journal-title":"J Am Med Dir Assoc"},{"key":"1019_CR225","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/j.1532-5415.2011.03406.x","volume":"59","author":"P Vergidis","year":"2011","unstructured":"Vergidis P, Hamer DH, Meydani SN, Dallal GE, Barlam TF. Patterns of antimicrobial use for respiratory tract infections in older residents of long-term care facilities. J Am Geriatr Soc. 2011;59:1093\u20138. https:\/\/doi.org\/10.1111\/j.1532-5415.2011.03406.x.","journal-title":"J Am Geriatr Soc"},{"key":"1019_CR226","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab048","volume":"3","author":"N Nguyen-Hoang","year":"2021","unstructured":"Nguyen-Hoang N, Bui QTH. Assessing the appropriateness of antimicrobial therapy in patients with sepsis at a Vietnamese national hospital. JAC-Antimicrobial Resistance. 2021;3: dlab048. https:\/\/doi.org\/10.1093\/jacamr\/dlab048.","journal-title":"JAC-Antimicrobial Resistance."},{"key":"1019_CR227","doi-asserted-by":"publisher","first-page":"1018158","DOI":"10.3389\/fphar.2022.1018158","volume":"13","author":"M N\u00fa\u00f1ez-N\u00fa\u00f1ez","year":"2022","unstructured":"N\u00fa\u00f1ez-N\u00fa\u00f1ez M, Perez-Galera S, Gir\u00f3n-Ortega JA, Sandoval Fern\u00e1ndez-Del-Castillo S, Beltr\u00e1n-Garc\u00eda M, De Cueto M, et al. Predictors of inappropriate antimicrobial prescription: eight-year point prevalence surveys experience in a third level hospital in Spain. Front Pharmacol. 2022;13:1018158. https:\/\/doi.org\/10.3389\/fphar.2022.1018158.","journal-title":"Front Pharmacol"},{"key":"1019_CR228","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1017\/ice.2021.221","volume":"43","author":"D Uribe-Cano","year":"2022","unstructured":"Uribe-Cano D, Bahranian M, Jolles SA, Taylor LN, Miller JJ, Adibhatla SN, Crnich CJ. Comparison of criteria for determining appropriateness of antibiotic prescribing in nursing homes. Infect Control Hosp Epidemiol. 2022;43:860\u20133. https:\/\/doi.org\/10.1017\/ice.2021.221.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1019_CR229","doi-asserted-by":"publisher","unstructured":"Tarrant C, Krockow EM, Nakkawita WMID, Bolscher M, Colman AM, Chattoe-Brown E, Perera N, Mehtar S, Jenkins DR. Moral and contextual dimensions of \u201cinappropriate\u201d antibiotic prescribing in secondary care: a three-country interview study. 2020. https:\/\/doi.org\/10.3389\/fsoc.2020.00007.","DOI":"10.3389\/fsoc.2020.00007"},{"key":"1019_CR230","doi-asserted-by":"publisher","unstructured":"Hung Y-P, Chen P-L, Ho C-Y, Hsieh C-C, Lee C-H, Lee C-C, Ko W-C. Prognostic effects of inappropriate empirical antimicrobial therapy in adults with community-onset bacteremia: age matters. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.861032.","DOI":"10.3389\/fmed.2022.861032"},{"key":"1019_CR231","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.544235","volume":"12","author":"F Zhu","year":"2020","unstructured":"Zhu F, Li C, Chu F, Tian X, Zhu J. Target dysbiosis of gut microbes as a future therapeutic manipulation in Alzheimer\u2019s disease. Front Aging Neurosci. 2020;12: 544235. https:\/\/doi.org\/10.3389\/fnagi.2020.544235.","journal-title":"Front Aging Neurosci."},{"key":"1019_CR232","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l440","volume":"364","author":"KB Pouwels","year":"2019","unstructured":"Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, McNulty CA, Robotham JV. Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. BMJ. 2019;364: l440. https:\/\/doi.org\/10.1136\/bmj.l440.","journal-title":"BMJ"},{"key":"1019_CR233","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3892\/etm.2017.4135","volume":"13","author":"B Xiao","year":"2017","unstructured":"Xiao B, Wang M, Hu X, Li J, Wang F, Sun J. Antibiotic de-escalation principle in elderly patients with chronic obstructive pulmonary disease complicated with severe pneumonia. Exp Ther Med. 2017;13:1485\u20139. https:\/\/doi.org\/10.3892\/etm.2017.4135.","journal-title":"Exp Ther Med"},{"key":"1019_CR234","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3947\/ic.2019.51.2.217","volume":"51","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Park KH, Park DA, Park J, Bang BW, Lee SS, et al. Guideline for the antibiotic use in acute gastroenteritis. Infect Chemotherapy. 2019;51:217\u201343. https:\/\/doi.org\/10.3947\/ic.2019.51.2.217.","journal-title":"Infect Chemotherapy"},{"key":"1019_CR235","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8090084","author":"M Helde-Frankling","year":"2016","unstructured":"Helde-Frankling M, Bergqvist J, Bergman P, Bj\u00f6rkhem-Bergman L. Antibiotic treatment in end-of-life cancer patients-a retrospective observational study at a palliative care center in Sweden. Cancers (Basel). 2016. https:\/\/doi.org\/10.3390\/cancers8090084.","journal-title":"Cancers (Basel)."},{"key":"1019_CR236","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-4-13","author":"L Rodriguez-Ma\u00f1as","year":"2020","unstructured":"Rodriguez-Ma\u00f1as L. Urinary tract infections in the elderly: a review of disease characteristics and current treatment options. Drugs Context. 2020. https:\/\/doi.org\/10.7573\/dic.2020-4-13.","journal-title":"Drugs Context."},{"key":"1019_CR237","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40266-018-0541-7","volume":"35","author":"I van Heijl","year":"2018","unstructured":"van Heijl I, Schweitzer VA, Zhang L, van der Linden PD, van Werkhoven CH, Postma DF. Inappropriate use of antimicrobials for lower respiratory tract infections in elderly patients: patient- and community-related implications and possible interventions. Drugs Aging. 2018;35:389\u201398. https:\/\/doi.org\/10.1007\/s40266-018-0541-7.","journal-title":"Drugs Aging"},{"key":"1019_CR238","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1017\/S0950268819000128","volume":"147","author":"NJ Bennett","year":"2019","unstructured":"Bennett NJ, Imam N, Ingram RJ, James RS, Buising KL, Bull AL, Chen CS, Thursky KA, Worth LJ. Skin and soft tissue infections and current antimicrobial prescribing practices in Australian aged care residents. Epidemiol Infect. 2019;147:e87\u2013e87. https:\/\/doi.org\/10.1017\/S0950268819000128.","journal-title":"Epidemiol Infect"},{"key":"1019_CR239","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.2147\/idr.S290835","volume":"13","author":"MAA Majumder","year":"2020","unstructured":"Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. Infect Drug Resist. 2020;13:4713\u201338. https:\/\/doi.org\/10.2147\/idr.S290835.","journal-title":"Infect Drug Resist."},{"key":"1019_CR240","doi-asserted-by":"publisher","unstructured":"Elango D. General Principles of Antimicrobial Therapy. In: Paul A, Anandabaskar N, Mathaiyan J, Raj GM (eds). Introduction to Basics of Pharmacology and Toxicology. Vol 2. Essentials of Systemic Pharmacology: From Principles to Practice. Singapore: Springer Nature Singapore; 2021. pp. 795-806. https:\/\/doi.org\/10.1007\/978-981-33-6009-9.","DOI":"10.1007\/978-981-33-6009-9"},{"key":"1019_CR241","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1039\/C7MD00528H","volume":"9","author":"RJ Melander","year":"2018","unstructured":"Melander RJ, Zurawski DV, Melander C. Narrow-spectrum antibacterial agents. MedChemComm. 2018;9:12\u201321. https:\/\/doi.org\/10.1039\/C7MD00528H.","journal-title":"MedChemComm."},{"key":"1019_CR242","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10096-010-0964-5","volume":"29","author":"E Raineri","year":"2010","unstructured":"Raineri E, Crema L, Dal Zoppo S, Acquarolo A, Pan A, Carnevale G, Albertario F, Candiani A. Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2010;29:1015\u201324. https:\/\/doi.org\/10.1007\/s10096-010-0964-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1019_CR243","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00134-019-05871-z","volume":"46","author":"JJ De Waele","year":"2020","unstructured":"De Waele JJ, Schouten J, Beovic B, Tabah A, Leone M. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions-a viewpoint of experts. Intensive Care Med. 2020;46:236\u201344. https:\/\/doi.org\/10.1007\/s00134-019-05871-z.","journal-title":"Intensive Care Med"},{"key":"1019_CR244","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/jgs.15675","volume":"67","author":"JH Wu","year":"2019","unstructured":"Wu JH, Langford BJ, Daneman N, Friedrich JO, Garber G. Antimicrobial stewardship programs in long-term care settings: a meta-analysis and systematic review. J Am Geriatr Soc. 2019;67:392\u20139. https:\/\/doi.org\/10.1111\/jgs.15675.","journal-title":"J Am Geriatr Soc"},{"key":"1019_CR245","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/jgs.12784","volume":"62","author":"S Zimmerman","year":"2014","unstructured":"Zimmerman S, Sloane PD, Bertrand R, Olsho LE, Beeber A, Kistler C, Hadden L, Edwards A, Weber DJ, Mitchell CM. Successfully reducing antibiotic prescribing in nursing homes. J Am Geriatr Soc. 2014;62:907\u201312. https:\/\/doi.org\/10.1111\/jgs.12784.","journal-title":"J Am Geriatr Soc"},{"key":"1019_CR246","unstructured":"US FDA. Amoxicillin\/clavulanate (Augmentin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR247","unstructured":"US FDA. Cefazolin (Ancef) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/50461slr139_ancef_lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR248","unstructured":"US FDA. Cefepime (Maxipime) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050679s036lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR249","unstructured":"US FDA. Cefotaxime (Claforan) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/050547s071,050596s042lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR250","unstructured":"US FDA. Cefoxitin (Mefoxin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050517s047lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR251","unstructured":"US FDA. Ceftazidime (Fortaz) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050578s062lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR252","unstructured":"US FDA. Ceftriaxone (Rocephin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/0550585s063lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR253","unstructured":"US FDA. Cefuroxime (Ceftin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050605s042lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR254","unstructured":"US FDA. Cefuroxime (Zinacef) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2001\/50643s11lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR255","unstructured":"US FDA. Cephalexin (Keflex) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/050405s097lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR256","unstructured":"US FDA. Clindamycin hidrochloride (Cleocine) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/050162s092s093lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR257","unstructured":"US FDA. Clindamycin (Cleocin Phosphate) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050441s055,050639s016lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR258","unstructured":"US FDA. Daptomycin (Cubicin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208385s005lbl.pdf. Accesseed 15 Feb 2023."},{"key":"1019_CR259","unstructured":"US FDA. Ertapenem (Invanz) [package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021337s019lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR260","unstructured":"US FDA. Imipenem and cilastatin (Primaxin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050587s074lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR261","unstructured":"US FDA. Isoniazid (Isoniazid) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/008678s028lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR262","unstructured":"US FDA. Meropenem (Merrem) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050706s037lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR263","unstructured":"US FDA. Piperacillin\/Tazobactam (Zosyn) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050684s88s89s90_050750s37s38s39lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR264","unstructured":"US FDA. Nitrofurantoin (nitrofurantoin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020064s019lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR265","unstructured":"US FDA. Oxacillin (oxacillin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/050640s017lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR266","unstructured":"US FDA. Ticarcillin (Timentin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/050590s069,050658s031lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR267","unstructured":"US FDA. Vancomycin (Vancocin) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050606s028lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR268","unstructured":"US FDA. Vancomycin hydrochloride (Vancocin HCL) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/060180s047lbl.pdf. Accessed 15 Feb 2023."},{"key":"1019_CR269","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ftd.0000000000000951","volume":"44","author":"DJE Marriott","year":"2022","unstructured":"Marriott DJE, Cattaneo D. Special issue on the therapeutic drug monitoring of anti-infective drugs: editorial. Ther Drug Monit. 2022;44:1\u20132. https:\/\/doi.org\/10.1097\/ftd.0000000000000951.","journal-title":"Ther Drug Monit"},{"key":"1019_CR270","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40266-015-0292-7","volume":"32","author":"CJ Crnich","year":"2015","unstructured":"Crnich CJ, Jump R, Trautner B, Sloane PD, Mody L. Optimizing antibiotic stewardship in nursing homes: a narrative review and recommendations for improvement. Drugs Aging. 2015;32:699\u2013716. https:\/\/doi.org\/10.1007\/s40266-015-0292-7.","journal-title":"Drugs Aging"},{"key":"1019_CR271","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154409","author":"G Mandelli","year":"2022","unstructured":"Mandelli G, Dore F, Langer M, Garbero E, Alagna L, Bianchin A, et al. Effectiveness of a multifaced antibiotic stewardship program: a pre-post study in seven Italian ICUs. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11154409.","journal-title":"J Clin Med"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-023-01019-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:13:14Z","timestamp":1744715594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-023-01019-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":271,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s40266-023-01019-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"27 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Luca Soraci, Antonio Cherubini, Luca Paoletti, Gianfranco Filippelli, Filippo Luciani, Pasqualina Lagan\u00e0, Maria Elsa Gambuzza, Elvira Filicetti, Andrea Corsonello, and Fabrizia Lattanzio declare they have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests\/competing interests"}},{"value":"This review article did not require approval by an Ethics Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All authors wrote the review and corrected the text. ACo and LS supervised the writing of the review and corrected the final version of the article. All authors contributed to the article and approved the submitted version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}